Investment Rating - The report maintains a "Buy" rating for key stocks in the industry, including Dongyangguang, Zhongyan Dadi, and Weixing Chemical [5]. Core Insights - The report emphasizes the potential of AI for Science (AI4S) in revolutionizing scientific research and its applications in various industries, particularly in materials and pharmaceuticals [1][2][3]. - AI4S is expected to grow into a significant market, potentially reaching a value of $140 billion if penetration rates increase to 25% in relevant sectors [3]. - China is identified as a favorable environment for the emergence of AI4S leaders due to its comprehensive chemical manufacturing capabilities and a shift towards research and development [4]. Summary by Sections Industry Overview - AI4S is recognized as the fifth paradigm of scientific research, integrating machine learning and high-performance computing to enhance research efficiency [1]. - The pharmaceutical sector is currently the largest market for AI4S, with major companies like Pfizer and Johnson & Johnson actively investing in this technology [2]. Market Potential - The report forecasts that AI4S could cover a downstream market size of approximately $11 trillion across six key sectors, including chemicals and semiconductors [3]. - If the research penetration rate reaches 2.5%, the AI4S industry could generate around $14.9 billion, with potential growth to $140 billion at a 25% penetration rate [3]. Key Companies - The report highlights key companies such as Crystal Technology and Zhizhi New Materials, which are making strides in AI4S applications in new materials [4]. - Notable collaborations include Crystal Technology's partnership with GCL Group for renewable materials R&D, with a total contract value of approximately 1 billion yuan [2]. Stock Performance - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for key stocks, indicating a positive outlook for companies like Dongyangguang and Zhongyan Dadi [5].

Core Insights - The report maintains a positive outlook on the HIV sector, highlighting Gilead's long-acting therapy, Lenacapavir, as a potential game-changer in HIV treatment and prevention [1][3]. Group 1: HIV Mechanism and Treatment - HIV is a retrovirus that selectively targets CD4+ cells, integrating its genetic material into the host's genome, leading to viral replication [5][7]. - The primary treatment for AIDS is the "cocktail therapy," which combines multiple antiviral drugs to minimize resistance and maximize viral suppression [5][7]. Group 2: Lenacapavir's Impact - Lenacapavir is Gilead's first long-acting HIV capsid inhibitor, showing promising results in clinical trials for treating multi-drug resistant HIV in adults [9][11]. - In the CAPELLA study, 83% of participants using Lenacapavir achieved a viral load of less than 50 copies/mL after 52 weeks, compared to only 11% in the placebo group [13][14]. - Lenacapavir has significant potential in post-exposure prophylaxis (PrEP), with studies indicating a 100% reduction in HIV infection risk among participants receiving biannual injections [20][21]. Group 3: Market Potential and Future Developments - The global HIV infection rate in 2023 was approximately 39.9 million, with a significant portion of the population being women [15][18]. - Lenacapavir's approval for PrEP is anticipated to set a new standard in HIV prevention, potentially generating substantial revenue for Gilead [23]. - Other recent advancements in HIV treatments include Merck's dual-drug therapy achieving positive results in Phase III trials and ViiV Healthcare's long-acting antibody therapy showing good efficacy [24][26].

Investment Rating - The report initiates coverage with a "BUY" rating for the company [5][17][20]. Core Insights - The company is positioned in the commercialization stage, focusing on innovative drug development across oncology, cardiovascular-metabolic, autoimmune, and ophthalmology sectors, with over 10 innovative drugs launched in China and three products under NMPA review [2][13][27]. - A diversified product portfolio is expected to drive significant revenue growth, with projected product sales exceeding RMB 8.2 billion in 2024, representing over 40% year-on-year growth [2][14][20]. - The oncology pipeline includes advanced products such as IBI363 and IBI343, which are in various clinical stages and show promising early efficacy and safety data [3][15][47]. Financial Projections - Revenue forecasts for 2024, 2025, and 2026 are RMB 82.4 billion, RMB 107.1 billion, and RMB 132.9 billion, respectively, with a narrowing net loss expected in 2024 and a return to profitability by 2025 [5][20][22]. - The target price is set at HK$ 59.6, indicating a potential upside of 53% from the current price [5][20][17]. Product Pipeline and Development - The company has a robust pipeline with four innovative drugs in phase III clinical stages and over 20 drugs in clinical development, including key products targeting obesity, diabetes, and various cancers [4][16][21]. - The non-oncology pipeline is also gaining traction, with significant products like mazdutide expected to receive approval in the first half of 2025, enhancing the company's market position in the cardiovascular and metabolic sectors [4][16][23]. Market Position and Competitive Advantage - The company has established a leading position in the GLP-1 market with mazdutide, which is anticipated to capture significant market share due to its first-mover advantage and commercialization capabilities [23][24]. - The oncology strategy focuses on "IO+ADC," leveraging advanced antibody technology and differentiated linker-payload platforms to enhance drug efficacy and safety [3][47].

Core Viewpoint - The article emphasizes the importance of defensive stocks in the current global trade tensions, highlighting companies that are expected to maintain stability and growth potential during market volatility [2]. Group 1: Merck (NYSE: MRK) - Merck is a global pharmaceutical giant known for its innovative medical solutions, with a product range that includes cutting-edge cancer drugs, vaccines, and prescription medications [5]. - The company exhibits strong defensive characteristics with a low beta coefficient of 0.36, a high dividend yield of 3.48%, and an impressive return on equity (ROE) of 40.8% [6]. - Current stock price is $94, significantly undervalued compared to a fair value estimate of $121.83, indicating a potential upside of 29.6% [6]. - Analysts have a strong buy rating for Merck, with target prices ranging from $95 to $146, averaging $112.78 [6]. Group 2: NextEra Energy (NYSE: NEE) - NextEra Energy is a leading utility company in the renewable energy sector, employing a strategy that combines traditional and clean energy sources [12]. - The company has a beta value of 0.57, a dividend yield of 3.2%, and operates in a regulated environment, making it less susceptible to trade disputes [13]. - Current stock price is $70.01, with analysts projecting a potential increase of 20%, as target prices range from $52 to $103, averaging $84.27 [13]. - NextEra's strong cash flow and commitment to sustainable development position it as a stable investment during turbulent market conditions [14]. Group 3: Tyson Foods (NYSE: TSN) - Tyson Foods is a major player in the food processing industry, offering a wide range of meat products including beef, pork, and poultry [18]. - The company has defensive traits with a beta value of 0.71, a dividend yield of 3.3%, and a dominant market position in various meat product categories [19]. - Current stock price is $60.53, with a fair value estimate of $75.83, suggesting a potential upside of nearly 25% [19]. - Analysts have a buy rating for Tyson, with target prices ranging from $58 to $80, reflecting its strong position in the supply chain and limited exposure to trade conflicts [20].

Investment Rating - The report does not explicitly state an investment rating for the industry [5] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.06%, underperforming compared to the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare sector experienced a significant rebound [10][11] - Key sectors that performed well include in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%). Conversely, offline pharmacies (-0.59%) and medical devices (-0.08%) saw declines [10][11] - The government work report emphasized strengthening basic medical and health services, implementing a health-first development strategy, and promoting the coordinated development of healthcare, medical insurance, and pharmaceuticals [12][14] - On March 8, Huawei announced the establishment of a healthcare division, aiming to integrate its expertise in 5G, cloud computing, and edge computing to develop AI-assisted diagnostic solutions [12][14] Weekly Market Review - The pharmaceutical and biotechnology sector increased by 1.06%, lagging behind the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare direction showed a notable rebound [10] - The top-performing sub-sectors included in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%), while offline pharmacies (-0.59%) and medical devices (-0.08%) were the worst performers [10][11] - The top three gaining stocks were Hotgen Biotech (38.63%), Berry Genomics (34.39%), and Anbiping (25.72%), while the top three losing stocks were Jiangsu Wuzhong (-14.34%), ST Sansheng (-9.83%), and Baile Tianheng-U (-9.44%) [12][14] Industry News and Key Company Announcements - The government work report highlighted the need to enhance basic medical services and improve the healthcare system, including reforms in public hospitals and drug procurement policies [12][14] - Huawei's new healthcare division aims to leverage its technological strengths to accelerate the development of medical AI models for clinical applications [12][14] - On March 8, Ausgen announced that the FDA accepted its new drug application for AUKONTALS, a treatment for amyotrophic lateral sclerosis, with a decision expected by October 23, 2025 [12][14] - CloudTop announced the successful administration of its mRNA personalized cancer vaccine EVM16 in a clinical trial, marking a significant milestone in its development [12][14]

Core Viewpoint - JD Health's 2024 annual performance announcement marks a new value benchmark for China's internet healthcare industry, showcasing strong revenue and profit growth driven by digital technology and new health consumption trends [1][2]. Revenue and Profit Performance - In 2024, JD Health reported total revenue of RMB 58.2 billion and a non-IFRS net profit of RMB 4.79 billion, both exceeding market expectations [2]. Reshaping Channel Efficiency - Health consumption has become a significant trend, with the government emphasizing the need for diverse service supply in health, elderly care, and other sectors. JD Health has restructured supply chain efficiency through a "self-operated + platform + instant retail" model, enhancing health consumption scenarios and expanding service reach [2]. Online Drug Sales Growth - The online drug purchasing mindset is maturing, with e-commerce channels becoming a core growth driver in the outpatient drug retail market. In 2024, China's pharmaceutical retail market reached RMB 501.9 billion, with e-commerce drug sales at RMB 64.5 billion, growing by 4.6% year-on-year, outpacing physical pharmacies [3]. Strengthening Partnerships with Pharmaceutical Companies - JD Health has enhanced its self-operated advantages and deepened collaborations with global pharmaceutical companies, facilitating the online launch of nearly 30 new specialty drugs in 2024 [3]. Instant Retail Expansion - JD Health is making strides in instant retail, particularly with its "online drug purchase with medical insurance account payment" service, which is now available in nearly 20 cities and connects over 3,000 medical insurance designated pharmacies, covering over 100 million people [4]. AI as a Core Driver of Change - AI is becoming a central driver of transformation in the healthcare industry, with the government promoting "AI+" initiatives to integrate digital technology with market advantages [5][6]. Development of AI Applications - JD Health has been an early mover in AI within the internet healthcare sector, developing its medical AI model "Jingyi Qianxun," which has extensive application scenarios and partnerships with hospitals [7]. Enhancing Healthcare Services with AI - JD Health is leveraging AI to improve healthcare service efficiency, allowing AI to handle tasks traditionally performed by doctors, thus enabling them to focus on more valuable patient interactions [7]. Broader Impact of AI in Healthcare - AI is not only enhancing JD Health's service efficiency but is also reshaping the entire healthcare industry, providing significant value in resource supply and patient care [8]. Vision for the Future - JD Health aims to set a benchmark for "efficiency and warmth" in the industry through digital innovation and efficiency transformation, contributing to the evolution of China's internet healthcare sector [8].

证券研究报告 海外MNC动态跟踪系列（八） 默沙东：K药卫冕药王宝座，索特西普表现亮眼 医药 强于大市（维持） 平安证券研究所 医药团队 分析师： 研究助理： 叶寅 投资咨询资格编号:S1060514100001 邮箱：YEYIN757@PINGAN.COM.CN 韩盟盟 投资咨询资格编号:S1060519060002 邮箱：HANMENGMENG005@PINGAN.COM.CN 张梦鸽 一般证券从业资格编号:S1060124120037 邮箱：ZHANGMENGGE752@PINGAN.COM.CN 2025年3月4日 请务必阅读正文后免责条款 行业观点 2025 年，默沙东重点数据读出如下： 2 事件：2月4日，默沙东公布2024年业绩，总营收641.68亿美元，同比增长7%。2024年全年每股收益为7.65美元（按非GAAP计算），2024年研发 支出为179亿美元。从营收情况看，业绩主要由帕博利珠单抗、四价/九价人乳头瘤病毒疫苗和动物保健板块贡献，其中帕博利珠单抗2024年实 现销售额295亿美元，继续蝉联"药王"宝座，HPV疫苗2024年实现收入86亿美元，动物保健板块2024年实现收入59亿美元 ...

Core Viewpoint - The article discusses the evolution of the HPV vaccine market in China, highlighting the challenges and changes in demand, pricing, and competition among vaccine manufacturers, particularly focusing on Merck's HPV vaccines and the emergence of domestic competitors [1][2][3]. Group 1: HPV Vaccine Market Dynamics - The HPV vaccine market in China has seen significant fluctuations, with Merck's four-valent and nine-valent vaccines initially experiencing high demand but later facing a decline in sales due to market saturation and competition from domestic vaccines [7][8][30]. - The introduction of domestic two-valent HPV vaccines at lower prices has intensified competition, leading to a price war that has drastically reduced the cost of HPV vaccines in China, with prices dropping below 200 yuan per dose [26][29]. - By August 2024, the price of the two-valent HPV vaccine had plummeted to 27.5 yuan per dose, reflecting the aggressive pricing strategies adopted by domestic manufacturers [29]. Group 2: Impact on Merck and Domestic Competitors - Merck's nine-valent HPV vaccine maintained a stable price due to its unique market position, but the increasing affordability of domestic vaccines has eroded its market share, particularly among cost-sensitive consumers [16][30]. - Despite Merck's strong sales growth in the past, with a 136.16% year-on-year increase in the number of nine-valent vaccines sold in 2023, the company faces challenges as the overall market for HPV vaccines in China is experiencing a decline in total issuance [30][33]. - Domestic manufacturers like Wantai and Watson have entered the market, leading to a significant shift in the competitive landscape, with both companies struggling to maintain profitability amid falling prices [29][36]. Group 3: Public Health Implications - The article emphasizes the public health significance of HPV vaccination, noting that cervical cancer remains a leading cause of cancer death among women globally, particularly in developing countries [42][44]. - The disparity in vaccine access and affordability highlights a broader issue of health equity, as lower-income populations are often unable to afford vaccines despite their necessity for cancer prevention [43][49]. - Initiatives for free or subsidized HPV vaccinations in certain regions, such as Inner Mongolia, demonstrate efforts to improve access and reduce the burden of cervical cancer, potentially setting a precedent for broader public health strategies [45][48].

Group 1: Market Overview - In 2023, 70 sample American companies generated over $3,000 billion in revenue from the Chinese market, contributing 12% to their global revenue[6] - The total global revenue of these companies exceeded $2.5 trillion, with a year-on-year growth of 1.1%[6] - The average revenue from the Chinese market for these companies was $4.39 billion, with a median of $2.16 billion[30] Group 2: Investment Trends - In 2023, the actual foreign investment in China reached $163.25 billion, ranking China as the second-largest recipient of foreign investment globally[15] - The number of newly established foreign-invested enterprises in China increased by 39.7% year-on-year, totaling 54,000[15] - The compound annual growth rate of U.S. investment in China from 2020 to 2023 was 13.5%, significantly higher than the overall growth rate of 3% for foreign investment in China[20] Group 3: Industry Performance - The consumer sector in China saw a compound annual growth rate of 19.4% from 2020 to 2023, double the global growth rate of 9.1%[50] - The healthcare sector in China grew by 16.8% during the same period, while the global healthcare market declined by 2%[59] - The information technology sector contributed the highest revenue share, averaging 25.7% of total revenue from the Chinese market[30]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Views - The report highlights that the Chinese innovative drug sector is expected to experience new growth logic due to internal and external policy catalysts, suggesting a focus on undervalued small-cap pharmaceutical stocks [5][6]. Summary by Sections 1. Innovative Drugs and Industry Chain - **Sangfor Pharmaceutical**: Core products show steady growth, with innovative pipelines gradually yielding results. The PD-1/VEGF dual antibody AK112 has become the first to defeat K drug in head-to-head Phase III trials, enhancing the development heat for PD(L)-1/VEGF dual antibodies [10][11]. - **Kojin Pharmaceutical**: The CAR-T therapy shows significant potential, with its first product, CT053, approved for multiple myeloma treatment. Another product, CT041, is expected to submit NDA in mid-2025 [12][13]. - **Hotgen Biotech**: The SGC001 drug for acute myocardial infarction is progressing through clinical trials, with promising preclinical data indicating significant therapeutic effects [20][21]. - **Kangfang Biotech**: The company is advancing its IO+ADC strategy, with two dual antibodies already approved. It is collaborating with Pfizer to explore combination therapies for various solid tumors [30][34]. - **Kolin Biotech**: The company is expanding its international clinical trials with Merck, focusing on multiple cancer types [36][40]. 2. Market Performance Review - The pharmaceutical sector index fell by 2.7% from February 24 to February 28, 2025, underperforming the CSI 300 index by 0.5%. However, year-to-date, the sector has risen by 1.1%, outperforming the CSI 300 by 2.3% [43][44]. 3. Investment Strategy and Focus - The report suggests focusing on four main investment lines: 1) Oversold blue-chip stocks and Hong Kong stocks, 2) Companies with positive short-term changes and low price-to-book ratios, 3) Firms with solid fundamentals, and 4) Companies expected to show high growth in H2 2024 [7][8]. - Recommended stocks include Kangfang Biotech, Zai Lab, Kolin Biotech, and others [7]. 4. Industry Outlook - The report anticipates a recovery in the demand for innovative drugs, driven by supportive government policies and increased investment in the biotech sector. This recovery is expected to benefit upstream companies and CRO services [42].